Proteomic analysis on the antibacterial activity of a Ru(II) complex against Streptococcus pneumoniae

Xiao-Yan Yang1, Liang Zhang2, Jie Liu3

  • 1Key Laboratory of Functional Protein Research of Guangdong Higher Education Institutes, Institute of Life and Health Engineering, College of Life Science and Technology, Jinan University, Guangzhou 510632, China; The First Affiliated Hospital of Jinan University,Guangzhou 510632, China.

Journal of Proteomics
|December 16, 2014
PubMed

Insights

A novel Ruthenium(II) complex, X-03, shows potent antibacterial activity against Streptococcus pneumoniae. Proteomic analysis reveals X-03 disrupts bacterial fatty acid synthesis and iron uptake, offering a new avenue for antibiotic development.

Area of Science:

  • Microbiology
  • Biochemistry
  • Materials Science

Background:

  • Antibiotic resistance is a growing global health threat.
  • Novel antibacterial agents are crucial to combat resistant pathogens.
  • Streptococcus pneumoniae is a significant human pathogen.

Purpose of the Study:

  • To evaluate the in vitro antibacterial activity of a Ruthenium(II) complex (X-03) against Streptococcus pneumoniae.
  • To investigate the antimicrobial mechanism of X-03 using proteomic and bioinformatics approaches.
  • To assess the cytotoxicity of X-03 against human host cells.

Main Methods:

  • In vitro antibacterial assays against Streptococcus pneumoniae.
  • Two-dimensional gel electrophoresis (2-DE) based proteomic analysis.
  • Reverse transcription polymerase chain reaction (RT-PCR) for gene expression validation.
  • Bioinformatics analysis of proteomic data.
  • Metal-uptake experiments, specifically for iron.

Main Results:

  • Ruthenium(II) complex X-03 demonstrated significant antibacterial activity against S. pneumoniae.
  • Proteomic analysis identified 50 differentially expressed proteins, suggesting interference with fatty acid synthesis and oxidation-reduction processes.
  • X-03 treatment led to reduced iron content in S. pneumoniae, indicating disruption of iron acquisition pathways.
  • X-03 exhibited selective toxicity towards Gram-positive bacteria with minimal impact on human cells.

Conclusions:

  • Ruthenium(II) complex X-03 possesses significant antibacterial properties against S. pneumoniae.
  • The antimicrobial mechanism involves the disruption of essential bacterial pathways, including fatty acid metabolism and iron uptake.
  • X-03 shows potential as a specific antimicrobial agent due to its selective toxicity.
  • Further research into metal-based compounds is warranted for developing new antibacterial drugs.